MX384146B - Triple combinación de antagonistas del receptor de 5-ht6 puro, inhibidores de acetilcolinesterasa y antagonista del receptor de nmda. - Google Patents
Triple combinación de antagonistas del receptor de 5-ht6 puro, inhibidores de acetilcolinesterasa y antagonista del receptor de nmda.Info
- Publication number
- MX384146B MX384146B MX2018014184A MX2018014184A MX384146B MX 384146 B MX384146 B MX 384146B MX 2018014184 A MX2018014184 A MX 2018014184A MX 2018014184 A MX2018014184 A MX 2018014184A MX 384146 B MX384146 B MX 384146B
- Authority
- MX
- Mexico
- Prior art keywords
- pure
- receptor antagonist
- nmda
- acetylcholinesterase inhibitors
- triple combination
- Prior art date
Links
- 108091005435 5-HT6 receptors Proteins 0.000 title abstract 3
- 239000000544 cholinesterase inhibitor Substances 0.000 title abstract 3
- 229940099433 NMDA receptor antagonist Drugs 0.000 title abstract 2
- 239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 title abstract 2
- 229940044551 receptor antagonist Drugs 0.000 title abstract 2
- 239000002464 receptor antagonist Substances 0.000 title abstract 2
- 229940100578 Acetylcholinesterase inhibitor Drugs 0.000 abstract 2
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 abstract 2
- 239000005557 antagonist Substances 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000003751 serotonin 6 antagonist Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Psychiatry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
- Indole Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La presente invención se relaciona con una combinación de antagonista del receptor de 5-HT6 puro, inhibidor de acetilcolinesterasa y antagonista del receptor de NMDA. Asimismo, la presente invención se relaciona con antagonistas del receptor de 5-HT6 (5-HT6R) o sales farmacéuticamente aceptables de los mismos en combinación con o como un adjunto del inhibidor de acetilcolinesterasa y el antagonista del receptor de N-metil-D-aspartato (NMDA) y su uso en el tratamiento de trastornos cognitivos. La presente invención proporciona además la composición farmacéutica que contiene dicha combinación.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201641017204 | 2016-05-18 | ||
| PCT/IB2016/054672 WO2017199070A1 (en) | 2016-05-18 | 2016-08-03 | Triple combination of pure 5-ht6 receptor antagonists, acetylcholinesterase inhibitors and nmda receptor antagonist |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2018014184A MX2018014184A (es) | 2019-02-25 |
| MX384146B true MX384146B (es) | 2025-03-14 |
Family
ID=56896730
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018014184A MX384146B (es) | 2016-05-18 | 2016-08-03 | Triple combinación de antagonistas del receptor de 5-ht6 puro, inhibidores de acetilcolinesterasa y antagonista del receptor de nmda. |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US11253514B2 (es) |
| EP (1) | EP3458039B1 (es) |
| JP (1) | JP6629464B2 (es) |
| KR (1) | KR102016120B1 (es) |
| CN (1) | CN109152751A (es) |
| AU (1) | AU2016407426B2 (es) |
| BR (1) | BR112018073410A2 (es) |
| CA (1) | CA3023836C (es) |
| CY (1) | CY1123644T1 (es) |
| DK (1) | DK3458039T3 (es) |
| EA (1) | EA038087B1 (es) |
| ES (1) | ES2815555T3 (es) |
| HK (1) | HK1258022A1 (es) |
| HR (1) | HRP20201412T1 (es) |
| HU (1) | HUE052077T2 (es) |
| IL (1) | IL262920B (es) |
| LT (1) | LT3458039T (es) |
| MA (1) | MA45002B1 (es) |
| MD (1) | MD3458039T2 (es) |
| MX (1) | MX384146B (es) |
| NZ (1) | NZ747797A (es) |
| PL (1) | PL3458039T3 (es) |
| PT (1) | PT3458039T (es) |
| RS (1) | RS60849B1 (es) |
| SG (1) | SG11201809726UA (es) |
| SI (1) | SI3458039T1 (es) |
| SM (1) | SMT202000521T1 (es) |
| WO (1) | WO2017199070A1 (es) |
| ZA (1) | ZA201807310B (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019008484A1 (en) * | 2017-07-03 | 2019-01-10 | Suven Life Sciences Limited | NEW USES OF A PURE 5-HT6 RECEPTOR ANTAGONIST |
| SMT202600019T1 (it) * | 2019-12-02 | 2026-03-09 | Suven Life Sciences Ltd | Masupirdina per il trattamento dei sintomi comportamentali e psicologici nella demenza |
| CN114761008B (zh) * | 2019-12-02 | 2024-07-19 | 苏文生命科学有限公司 | 用于在患有痴呆的患者中治疗行为和心理症状的方法 |
| CN117024326A (zh) * | 2023-07-26 | 2023-11-10 | 平顶山学院 | 5位氨基取代吲哚化合物及其制备方法和在抗乙酰胆碱酯酶药物中的应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003101458A1 (en) * | 2002-05-31 | 2003-12-11 | H. Lundbeck A/S | A combination of an nmda-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease |
| EP1581492B1 (en) | 2002-11-28 | 2008-07-16 | Suven Life Sciences Limited | N-arylsulfonyl-3-substituted indoles having serotonin receptor affinity, process for their preparation and pharmaceutical composition containing them |
| KR101463190B1 (ko) * | 2010-01-05 | 2014-11-18 | 수벤 라이프 사이언시스 리미티드 | ５ｈｔ６ 수용체 리간드인 술폰 화합물 |
| MX364930B (es) | 2013-12-02 | 2019-05-14 | Suven Life Sciences Ltd | Proceso de producción a gran escala de dimesilato de 1-[(2-bromofenil]sulfonil]-5-metoxi-3-[(4-metil-1-piperazinil)met il]-1h-indol monohidratado. |
| US9840482B2 (en) * | 2014-04-19 | 2017-12-12 | Sunshine Lake Pharma Co., Ltd. | Sulfonamide derivatives and pharmaceutical applications thereof |
-
2016
- 2016-08-03 SG SG11201809726UA patent/SG11201809726UA/en unknown
- 2016-08-03 ES ES16763575T patent/ES2815555T3/es active Active
- 2016-08-03 NZ NZ747797A patent/NZ747797A/en unknown
- 2016-08-03 WO PCT/IB2016/054672 patent/WO2017199070A1/en not_active Ceased
- 2016-08-03 PL PL16763575T patent/PL3458039T3/pl unknown
- 2016-08-03 BR BR112018073410-1A patent/BR112018073410A2/pt not_active Application Discontinuation
- 2016-08-03 HU HUE16763575A patent/HUE052077T2/hu unknown
- 2016-08-03 MA MA45002A patent/MA45002B1/fr unknown
- 2016-08-03 AU AU2016407426A patent/AU2016407426B2/en active Active
- 2016-08-03 JP JP2018559327A patent/JP6629464B2/ja active Active
- 2016-08-03 DK DK16763575.4T patent/DK3458039T3/da active
- 2016-08-03 SM SM20200521T patent/SMT202000521T1/it unknown
- 2016-08-03 PT PT167635754T patent/PT3458039T/pt unknown
- 2016-08-03 SI SI201630909T patent/SI3458039T1/sl unknown
- 2016-08-03 EA EA201892528A patent/EA038087B1/ru unknown
- 2016-08-03 CN CN201680085589.7A patent/CN109152751A/zh active Pending
- 2016-08-03 RS RS20201045A patent/RS60849B1/sr unknown
- 2016-08-03 EP EP16763575.4A patent/EP3458039B1/en active Active
- 2016-08-03 CA CA3023836A patent/CA3023836C/en active Active
- 2016-08-03 HK HK19100393.2A patent/HK1258022A1/zh unknown
- 2016-08-03 KR KR1020187035888A patent/KR102016120B1/ko active Active
- 2016-08-03 US US16/097,752 patent/US11253514B2/en active Active
- 2016-08-03 LT LTEP16763575.4T patent/LT3458039T/lt unknown
- 2016-08-03 HR HRP20201412TT patent/HRP20201412T1/hr unknown
- 2016-08-03 MX MX2018014184A patent/MX384146B/es unknown
- 2016-08-03 MD MDE20190349T patent/MD3458039T2/ro unknown
-
2018
- 2018-10-31 ZA ZA2018/07310A patent/ZA201807310B/en unknown
- 2018-11-11 IL IL262920A patent/IL262920B/en active IP Right Grant
-
2020
- 2020-09-04 CY CY20201100834T patent/CY1123644T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022007989A (es) | Composiciones y metodos para tratar pterigion. | |
| MX2017014192A (es) | Composiciones y metodos de tratamiento de una enfermedad neurodegenerativa. | |
| EA201990424A1 (ru) | Спиролактамовые модуляторы nmda-рецептора и их применение | |
| EA201792057A1 (ru) | Конденсированные бициклические гетероарильные производные с активностью ингибиторов пролилгидроксилазы | |
| WO2016109217A3 (en) | Btk inhibitors | |
| EA201990428A1 (ru) | Спиролактамовые модуляторы nmda-рецептора и их применение | |
| TW201713341A (en) | Compositions and methods of treating a neurodegenerative disease | |
| MX2020010568A (es) | Derivados de urea ciclica fusionada como antagonista de crhr2. | |
| CY1123644T1 (el) | Τριπλος συνδυασμος καθαρων ανταγωνιστων του υποδοχεα 5-ητ6, αναστολεων της ακετυλοχολινεστερασης και του ανταγωνιστη του υποδοχεα nmda | |
| CY1123013T1 (el) | Συνδυασμος των καθαρων ανταγωνιστων του υποδοχεα 5-ητ6 με τους αναστολεις της ακετυλοχολινεστερασης | |
| EA201791480A1 (ru) | Новые производные бензимидазола в качестве антигистаминных агентов | |
| CY1123185T1 (el) | Παραγωγα ινδολιου | |
| MX378799B (es) | Combinación de antagonistas del receptor 5-ht6 puro con un antagonista del receptor nmda. | |
| SA521421098B1 (ar) | -h4 مركبات بيريدو بيريميدينات كمثبطات مستقبل هستامين | |
| TN2017000248A1 (en) | Cgrp antagonist peptides | |
| PH12016502480A1 (en) | Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases | |
| MX377517B (es) | Combinacion triple de agonistas inversos del receptor de histamina 3, inhibidores de acetilcolinestearasa y antagonistas del receptor nmda. | |
| EA201692426A1 (ru) | Комбинации зальтопрофена и миорелаксанта | |
| CY1123238T1 (el) | Συνδυασμος antiστροφων αγωνιστων του υποδοχεα της ισταμινης-3 με αναστολεις της ακετυλοχολινεστερασης | |
| EA202090397A1 (ru) | Фторопиперидиновые соединения в качестве чистых антагонистов 5-ht-рецептора | |
| MX2017008497A (es) | Nuevos compuestos heterocíclicos y su uso tanto en medicina como en cosmética. |